Wednesday, January 12, 2022 5:04:48 AM
The only thing that matters are facts.
And they are bad:
- Insiders dumping more than 85% on their stocks while they were promising great news "soon"
- Stock price crashing over the last 18 months
- "Sure thing" promises by insiders never met - always a negative surprise
- "Sure thing" expectations by long investors never met - always a negative surprise
- All published study statistics failing to meet statistical standards (e.g., data dredging by looking at sub-pops that were NOT planned before in the statistical plan, WITHOUT the statistical corrections that are mandatory in these cases)
- Investigation by SEC and DOJ focused on the company and its insiders (NOT external investors)
- FDA taking the exceptional step to warn investors that Leronlimab has NOT been proven to work
- Judge publicly criticizing CEO's "unmitigated greed" and threatening
- CEO losing all past lawsuits against shareholders or employees
- Massive turnover of CxOs below the CEO
- CEO asking to his CRO to send an incomplete (=illegal) BLA to the FDA
- Company paying 11 STOCK PROMOTERS to pump its stock, a worldwide record for a 20 employees company
- Some of these promoters ACTING ILLEGALLY on various high traffic websites
REALITY IS SAD
And they are bad:
- Insiders dumping more than 85% on their stocks while they were promising great news "soon"
- Stock price crashing over the last 18 months
- "Sure thing" promises by insiders never met - always a negative surprise
- "Sure thing" expectations by long investors never met - always a negative surprise
- All published study statistics failing to meet statistical standards (e.g., data dredging by looking at sub-pops that were NOT planned before in the statistical plan, WITHOUT the statistical corrections that are mandatory in these cases)
- Investigation by SEC and DOJ focused on the company and its insiders (NOT external investors)
- FDA taking the exceptional step to warn investors that Leronlimab has NOT been proven to work
- Judge publicly criticizing CEO's "unmitigated greed" and threatening
- CEO losing all past lawsuits against shareholders or employees
- Massive turnover of CxOs below the CEO
- CEO asking to his CRO to send an incomplete (=illegal) BLA to the FDA
- Company paying 11 STOCK PROMOTERS to pump its stock, a worldwide record for a 20 employees company
- Some of these promoters ACTING ILLEGALLY on various high traffic websites
REALITY IS SAD
Recent CYDY News
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
